September 19, 2017 6:56 PM ET


Company Overview of Valbiotis SA

Company Overview

Valbiotis SA develops nutrition solutions to prevent cardiometabolic diseases and provides nutritional support for patients. The company develops Valedia, a product that is in Phase II clinical trial for the treatment of type 2 diabetes. Its products in Phase I/II clinical trials include VAL-63, a health supplement that is used for the prevention of non-alcoholic fatty liver disease; and VAL-630, a medical nutrition product, which provides nutritional support for patients with non-alcoholic steatohepatitis and type 2 diabetes. The company’s health supplement products under clinical development Phase comprise Lipidrive that regulates body weight by acting specifically on body fat mass; and VA...

40 rue Chef de Baie

La Rochelle,  17000


Founded in 2014

9 Employees

Key Executives for Valbiotis SA

Valbiotis SA does not have any Key Executives recorded.

Valbiotis SA Key Developments

Valbiotis SA Appoints Pascal SIRVENT as Director of Discovery and Preclinical Research

Valbiotis SA announced the arrival of Pascal SIRVENT as Director of Discovery and Preclinical Research from September 1st, 2017. Pascal SIRVENT has been contributing to company's growth for several years as a member of the Scientific Committee and head of collaborative projects between the University of Clermont Auvergne and VALBIOTIS. Co-inventor of several technologies crucial to the development of VALBIOTIS, Pascal has extensive preclinical research expertise. He has published some 30 articles in international scientific journals and given numerous presentations at congresses. With over 10 years experience in research, Pascal SIRVENT will be bringing his in-depth expertise in metabolic diseases and nutrition.

VALBIOTIS Opens New Clinical Investigation Center at the Institut Pasteur in Lille

VALBIOTIS announced the opening of a new Clinical Investigation Center at the Institut Pasteur in Lille as part of the Phase IIa study on Totum-63. Following the conclusive results obtained for the Phase I/II study, VALBIOTIS has initiated a Phase IIa study to demonstrate the efficacy of a high dose of the active ingredient of Valedia® on prediabetics (ultimate proof of efficacy). Like the three other trials carried out as part of the Phase II study, this Phase IIa is expected to be completed by 2019 in view of the submission of a proprietary health claim request, first, to the EFSA. This will make it possible to market the product in Europe by 2020, and then in the United States by 2021 after a health claim request has been submitted to the FDA, once EFSA approval has been obtained. The opening of this new Clinical Investigation Center at the Institut Pasteur in Lille which follows the opening of the first Biofortis Mérieux NutriSciences Clinical Investigation Center in Nantes in November 2016 will help accelerate the recruitment of volunteers for the Phase IIa clinical study. Professor Jean-Michel Lecerf is the investigator for the clinical study that will be conducted at this Clinical Investigation Center.

Valbiotis SAS Presents at BioMed Event by Invest Securities, Jan-26-2017

Valbiotis SAS Presents at BioMed Event by Invest Securities, Jan-26-2017 . Venue: Salons Hoche, 9 avenue Hoche, 75008 Paris, France.

Similar Private Companies By Industry

Company Name Region
Acticor Biotech SAS Europe
Ademtech SA Europe
Aelis Farma S.A.S. Europe
Aenitis Technologies SAS Europe
Alderys SAS Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Tax Management Inc United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Valbiotis SA, please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at